Imvax unveils positive results from clinical trial of IGV-001 vaccine
Category: #health  By Nikita Chaurasia  Date: 2019-04-01
  • share
  • Twitter
  • Facebook
  • LinkedIn

Imvax unveils positive results from clinical trial of IGV-001 vaccine

Clinical-stage biotechnology company Imvax, Inc., committed to creating novel patient-specific vaccines and immunotherapy strategies, has reportedly attained positive results from an ongoing Phase 1b clinical trial that proves treatment with IGV-001, the firm’s new autologous tumor cell vaccine, outdid standard of care (SOC) with progression-free survival (PFS) and prolonged overall survival (OS) among patients newly diagnosed glioblastoma multiforme (GBM).

The results were reportedly demonstrated through an oral presentation over the session of Advances in Novel Immunotherapeutic held at the American Association for Cancer Research Annual Meeting 2019, backs the consistent development of a new immunotherapy paradigm for treating GBM.

Anthony Alfred Chiurco, MD, Neurological Surgery Professor, Vice Chair of Clinical Services at Jefferson University’s Vickie and Jack Farber Institute for Neuroscience and David W. Andrews, M.D., Imvax’s Co-founder, Interim CEO, and Chief Medical Officer, said that the results evidently demonstrate that this new investigational vaccine displays promise when compared to currently practiced standard of care therapies.

The Phase 1b trial assessed the safety and efficiency of the autologous vaccine IGV-001, developed from patients’ tumor cells and an antisense formula, in newly diagnosed adult GBM patients, cite sources close to the development.

The trial reportedly involved thirty-three patients who received one of four vaccine exposures, while SOC treatment, for instance, radiotherapy, and temozolomide was introduced four to six weeks post vaccine administration. The main endpoint was safety, while tumor response was the secondary endpoint. Exploratory goals comprised of an assessment of OS, PFS, and immune markers, reported sources. In addition, a historical comparator group consisting of 35 newly diagnosed patients with GBM treated at the same center assessed SOC alone, stated sources familiar with the trial.

The treatment with IGV-001 was well tolerated with 15 of 33 patients experiencing no tumor growth as of March 1, 2019. Additionally, the cohort treated with the highest vaccine dose displayed an improvement of 7.3 months in OS and 3.5 months in PFS against SOC treatment alone, reported sources.
 

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Nikita Chaurasia    

Nikita Chaurasia

Having always been daft at wordplay, Nikita Chaurasia, post the completion of post-graduation, commenced her journey into the content generation cosmos. Endowed with a professional MBA degree in Advertising and Public Relations, Nikita strives to integrate her creativ...

Read More

More News By Nikita Chaurasia

GSK, Zymeworks expand partnership for bispecific antibody development
GSK, Zymeworks expand partnership for bispecific antibody development
By Nikita Chaurasia

GSK anticipates using Zymeworks’ Azymetric technology for developing bispecifics drugs that treat communicable diseases Zymeworks Inc, a clinical-stage biopharmaceutical company, has recently announced that GSK has extended its 2016 licensing ...

Vertex, Kymera join forces for developing protein degradation drugs
Vertex, Kymera join forces for developing protein degradation drugs
By Nikita Chaurasia

Vertex would be paying $70 million in advance to work with Kymera including an equity investment in the company Kymera Therapeutics and Vertex Pharmaceuticals Incorporated (VRTX) have reportedly announced that they are entering into a four-year rese...

Amazon plans job cuts as it deploys machines to pack orders
Amazon plans job cuts as it deploys machines to pack orders
By Nikita Chaurasia

Amazon is well known for its drive to automate as many segments of its business as possible. The American multinational technology company Amazon Inc. is reportedly planning to deploy machines to automate boxing up customer orders. The company has i...